Skip to content

Individualized Transcranial Magnetic Stimulation for Parkinson's Disease: Exploring Efficacy and Mechanisms of Brain Network Changes with Brain Imaging and Electroencephalography

Individualized Transcranial Magnetic Stimulation (iTMS) Guided by Resting-State Functional Magnetic Resonance Imaging (rs-fMRI) and Quantitative Electroencephalography (qEEG) for Parkinson's Disease: A Randomized Controlled Trial to Evaluate Efficacy and Brain Network Mechanisms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116181
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-30
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

Healthy control group:classical and conventional transcranial magnetic stimulation

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for idiopathic Parkinson's disease established by the International Parkinson and Movement Disorder Society (MDS). 2. Being at Hoehn and Yahr (H-Y) stage 1 to 3, with good cooperation and compliance. 3. Having a normal mental state and being able to cooperate with the completion of EEG, MRI, and clinical scale assessments.

Exclusion criteria

Exclusion criteria: 1. Secondary Parkinson's disease (PD) (e.g., drug-induced, cerebrovascular) or Parkinson-plus syndromes. 2. Comorbidity with severe physical diseases (e.g., acute myocardial infarction, hepatic or renal failure) or mental illnesses (e.g., depression, schizophrenia). 3. Contraindications to Transcranial Magnetic Stimulation (TMS) (e.g., history of epilepsy, intracranial metal implants, cardiac pacemaker) and contraindications to imaging examinations (e.g., claustrophobia, metal foreign bodies). 4. Previous receipt of neuromodulation therapies such as Deep Brain Stimulation (DBS), transcranial Direct Current Stimulation (tDCS), or repetitive Transcranial Magnetic Stimulation (rTMS). 5. Inability to receive regular treatment or attend follow-up visits (poor compliance).

Design outcomes

Primary

MeasureTime frame
Unified Parkinson's Disease Rating Scale;

Secondary

MeasureTime frame
Pittsburgh Sleep Quality Index;Hamilton Depression Rating Scale;

Countries

China

Contacts

Public ContactXiaoming Wang, Xiaoyan Zhou

Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China,

wangxm238@163.com+86 139 9076 9566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026